AKT1 and type 2 diabetes mellitus: Similarly, Zhang et al. demonstrated that HAS ameliorates the disease progression in type 2 diabetic mice via the PI3K/Akt/GSK-3β/GS pathway, thereby reducing blood glucose and increasing glycogen synthesis [53].